You are here:

azilsartan medoxomil (Edarbi)


in the absence of a submission from the holder of the marketing authorisation:

azilsartan medoxomil (Edarbi®) is not recommended for use within NHS Scotland.

Indication under review: treatment of essential hypertension in adults.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: azilsartan medoxomil (Edarbi)
SMC Drug ID: 803/12
Manufacturer: Takeda UK Ltd
Indication: Treatment of essential hypertension in adults.
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 9 July 2012